S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
China July exports rise, with trade surplus at record-high
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
China July exports rise, with trade surplus at record-high
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
China July exports rise, with trade surplus at record-high
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
China July exports rise, with trade surplus at record-high
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:DERM

Dermira (DERM) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$3.67
$4.15
50-Day Range
$18.73
$18.85
52-Week Range
$5.25
$19.48
Volume
7,943 shs
Average Volume
6,803 shs
Market Capitalization
$72.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Dermira MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
201.2% Upside
$12.50 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Dermira in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.77) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

751st out of 1,283 stocks

Pharmaceutical Preparations Industry

363rd out of 615 stocks

Dermira logo

About Dermira (NASDAQ:DERM) Stock

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Receive DERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermira and its competitors with MarketBeat's FREE daily newsletter.

DERM Stock News Headlines

The 3-Stock Retirement Blueprint
When most folks think about making money through the markets, they think “buy and hold.” They think “diversification.” And they think about investing in things like index funds. But one man has a different approach… It’s called the “3-Stock Retirement Blueprint.”
The 3-Stock Retirement Blueprint
When most folks think about making money through the markets, they think “buy and hold.” They think “diversification.” And they think about investing in things like index funds. But one man has a different approach… It’s called the “3-Stock Retirement Blueprint.”
See More Headlines

Receive DERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermira and its competitors with MarketBeat's FREE daily newsletter.

DERM Company Calendar

Last Earnings
5/10/2022
Today
8/07/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DERM
Fax
N/A
Employees
333
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+201.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-43,990,000.00
Pretax Margin
-67.10%

Debt

Sales & Book Value

Annual Sales
$63.13 million
Book Value
$2.43 per share

Miscellaneous

Free Float
15,649,000
Market Cap
$72.33 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Thomas G. Wiggans (Age 67)
    Co-Founder, CEO & Chairman
  • Dr. Eugene Andrew Bauer (Age 77)
    Co-Founder, Chief Medical Officer & Director
  • Mr. Andrew L. Guggenhime (Age 51)
    Chief Financial Officer
  • Ms. Lori Lyons-Williams (Age 42)
    Chief Commercial Officer
  • Mr. Christopher M. Griffith (Age 43)
    Co-Founder and Chief Bus. & Strategy Officer













DERM Stock - Frequently Asked Questions

Should I buy or sell Dermira stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dermira stock.
View analyst ratings for Dermira
or view top-rated stocks.

What is Dermira's stock price forecast for 2022?

3 equities research analysts have issued 12-month price objectives for Dermira's shares. Their DERM stock forecasts range from $10.00 to $15.00. On average, they expect Dermira's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 201.2% from the stock's current price.
View analysts' price targets for Dermira
or view top-rated stocks among Wall Street analysts.

Are investors shorting Dermira?

Dermira saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 8,400 shares, a decrease of 20.0% from the June 30th total of 10,500 shares. Based on an average daily trading volume, of 15,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company's shares are sold short.
View Dermira's Short Interest
.

When is Dermira's next earnings date?

Dermira is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Dermira
.

How can I listen to Dermira's earnings call?

Dermira will be holding an earnings conference call on Tuesday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) issued its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.10. The biopharmaceutical company had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.03 million. Dermira had a negative net margin of 60.28% and a negative trailing twelve-month return on equity of 86.39%.

What other stocks do shareholders of Dermira own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN).

When did Dermira IPO?

(DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share.

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

What is Dermira's stock price today?

One share of DERM stock can currently be purchased for approximately $4.15.

How much money does Dermira make?

Dermira (NASDAQ:DERM) has a market capitalization of $72.33 million and generates $63.13 million in revenue each year. The biopharmaceutical company earns $-43,990,000.00 in net income (profit) each year or ($4.18) on an earnings per share basis.

How many employees does Dermira have?

Dermira employs 333 workers across the globe.

How can I contact Dermira?

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The official website for Dermira is www.dermira.com. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at investor@dermira.com.

This page (NASDAQ:DERM) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.